63 related articles for article (PubMed ID: 10224336)
1. In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients.
Mikamo H; Sato Y; Hayasaki Y; Kawazoe K; Tamaya T
Chemotherapy; 1999; 45(3):154-7. PubMed ID: 10224336
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of E1101, a novel oral cephalosporin, against bacteria causing infections in obstetric and gynecological patients.
Mikamo H; Sato Y; Hayasaki Y; Kawazoe K; Tamaya T
Chemotherapy; 1998; 44(5):328-30. PubMed ID: 9732148
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
Kato N; Kato H; Tanaka-Bando K; Watanabe K; Ueno K
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antibacterial activities of AM-1155 in the fields of obstetrics and gynecology.
Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Izumi K; Tamaya T
Chemotherapy; 1998; 44(4):238-42. PubMed ID: 9681200
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of FK037, a new parenteral broad-spectrum cephalosporin, against recent clinical isolates in the fields of obstetrics and gynecology.
Mikamo H; Izumi K; Ito K; Katoh N; Watanabe K; Ueno K; Tamaya T
Chemotherapy; 1994; 40(3):161-6. PubMed ID: 8205934
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of telithromycin.
Mikamo H; Yin XH; Ninomiya M; Tamaya T
Chemotherapy; 2003 May; 49(1-2):62-5. PubMed ID: 12714813
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of an injectable new quinolone, pazufloxacin, against polymicrobial infections in the uterine endometritis model.
Mikamo H; Kawazoe K; Sato Y; Tamaya T
Chemotherapy; 1998; 44(2):99-102. PubMed ID: 9551239
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of a new carbapenem BO-2727 for use in obstetrics and gynecology.
Mikamo H; Kawazoe K; Izumi K; Sato Y; Tamaya T
Chemotherapy; 1998; 44(1):12-6. PubMed ID: 9444403
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.
Mikamo H; Izumi K; Hua YX; Hayasaki Y; Sato Y; Tamaya T
J Antimicrob Chemother; 2000 Sep; 46(3):471-4. PubMed ID: 10980177
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
Kato N; Kato H; Tanaka-Bandoh K; Watanabe K; Ueno K
J Antimicrob Chemother; 1997 Nov; 40(5):631-7. PubMed ID: 9421310
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial activities of tosufloxacin against anaerobic bacteria and the electron micrograph of its bactericidal effects.
Takahata M; Nishino T
Chemotherapy; 1997; 43(3):153-8. PubMed ID: 9142454
[TBL] [Abstract][Full Text] [Related]
14. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of a new fluoroquinolone, marbofloxacin (RO 09-1168) against strictly anaerobic bacteria and some bacteria from human fecal flora].
Dubreuil L; Houcke I; Leroy I
Pathol Biol (Paris); 1996 May; 44(5):333-6. PubMed ID: 8758470
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antibacterial activities of biapenem in the fields of obstetrics and gynecology.
Mikamo H; Sato Y; Hayasaki Y; Tamaya T
Chemotherapy; 2000; 46(2):95-9. PubMed ID: 10671758
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
[TBL] [Abstract][Full Text] [Related]
19. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
[TBL] [Abstract][Full Text] [Related]
20. Effect of aspoxicillin on anaerobic bacteria.
Ueno K; Watanabe K; Bunai M; Kobayashi T; Aoki M; Maezawa I; Sakuma Y; Yoshida H; Yamaguchi T
Jpn J Antibiot; 1985 Jun; 38(6):1516-28. PubMed ID: 3850132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
